Navigation Links
VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
Date:11/9/2011

CHARLESTON, S.C., Nov. 9, 2011 /PRNewswire/ -- VaxyGen Assay Services, LLC, today announced that it has commenced business operations, providing custom assay services, immunoassays, and database services in support of biopharmaceutical and vaccine development. The Company offers customized solutions to meet basic, applied, and clinical research demands, providing unique in vitro assays in support of research and development of novel biopharmaceutical and vaccine products operating through its GLP compliant laboratory facilities to support biomarker/immunoassay evaluation and development needs.

Commenting on the launch of VaxyGen Assay Services, David Dodd, CEO, stated, "We believe that our clients are best served through the successful combination of the highest expertise and support of science and business.  Our clients are committed to delivering innovative, life enhancing products.  VaxyGen Assay Services was founded to ensure that our clients can consistently rely on us to deliver them the highest quality client service and scientific service in support of their biological assay service needs.  Our Management Team reflects this commitment – most importantly, through their demonstrated experience in delivering such value to clients."

Leading the scientific and technical expertise at VaxyGen Assay Services is Joseph E. Martinez, Ph.D., a recognized expert in flow cytometry and multiplexed immunoassay development. Joseph is a research biologist with 25 years of flow cytometry experience. Prior to the formation of the VaxyGen family of companies, he spent 13 years as the head of the flow cytometry laboratory within the Respiratory Diseases Section at the Centers for Disease Control and Prevention. He has served as the Director of Research and Laboratory Services for several biotech companies. He has developed multiplexed immunological assays for the flow cytometric, Luminex, and ELISA platforms. Dr. Martinez is the lead inventor for US patents related to multiplex immunoassays, and is a co-inventor for an immunological adjunct molecule.

About VaxyGen Assay Services, LLC & VaxyGen Holdings, LLC

VaxyGen Assay Services (www.vaxygenassayservices.com) is a member of the VaxyGen Holdings, LLC (www.vaxygen.com) family of companies, consisting of VaxyGen Vaccines, Ltd., VaxyGen Manufacturing Services, LLC, VaxyGen Assay Services, LLC and, VaxyGen Management Company, LLC.  In June, 2011, the formation of VaxyGen Vaccines, Ltd., was announced in conjunction with an exclusive strategic agreement signed with the Serum Institute of India (www.seruminstitute.com), providing a novel, new vaccine business focused on delivering affordable innovation to improve immunization against life threatening conditions.  In October, 2011, the formation of VaxyGen Manufacturing Services, LLC was announced in conjunction with an exclusive agreement signed with the Georgia State University Research Foundation, providing a unique business collaboration with the Georgia State University Biological Process Development and Research Laboratory.

Contact:
Kathryn D. Gallagher
Director, Marketing & Operations
Tel: 843.789.5924; 1.888.753.7362
kgallagher@vaxygen.com


'/>"/>
SOURCE VaxyGen Assay Services, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. SwitchGear Genomics and New England Biolabs Develop New Multiplex Reporter Assay System
2. Early Adopter of INFORM HER2 Dual ISH Assay Optimistic About Impact on Patient Care, Hospital Bottom Line
3. Malaria Parasite and Mosquito Products and Assay Services Available for Sale by Sanaria
4. NextGen Sciences Launches Multiple Protein cerebrospinal fluid (CSF) CNS Disease Biomarker Assay
5. Avantra Biosciences Announces Significant Reduction In Multiplex Immunoassay Processing Time
6. Avantra Biosciences Announces the Launch of a Rapid Assay Prototyping Service
7. BD Diagnostics Receives FDA Clearance for First Fully Automated Molecular Assays for HSV1 and HSV2 from Clinician-Collected External Anogenital Lesion Specimens
8. Calipers Microfluidic Technologies Enable 510(k) Approved Multiplexed Immunoassay System for Liver Cancer Risk Assessment
9. Reimbursement Rate Nearly Tripled for Cylexs ImmuKnow® Assay
10. Prodesse ProAdeno™+ Assay Cleared for US Marketing by FDA
11. Transgenomic Develops New Assays to Detect EGFR Mutations Using COLD-PCR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... ... today that in a published evaluation of multiple immunoassay-based threat detection technologies ... of Energy Laboratory, PathSensors’ CANARY® biosensor threat detection technology was found to ...
(Date:2/23/2017)... 23, 2017  Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology ... today announced that Linda Marbán, Ph.D, president and chief executive ... Cowen and Company 37th Annual Health ... Boston, MA 29th ... PT (12:00 pm ET) Dana Point, CA ...
(Date:2/22/2017)... Kan. , Feb. 22, 2017  Aratana Therapeutics, Inc. ... development and commercialization of innovative biopharmaceutical products for companion animals, ... 2017 at 8:30 a.m. ET to discuss financial results from ... Interested participants and investors may access the ... ...
(Date:2/22/2017)... CINCINNATI , Feb. 22, 2017 Scientists ... drives inflammation and organ damage in Gaucher and maybe ... fewer risks and lower costs than current therapies. ... Children,s Hospital Medical Center , which also included investigators ... , report their data Feb. 22. The study ...
Breaking Biology Technology:
(Date:2/16/2017)...  Genos, a community for personal genetic discovery ... Laboratory Accreditation from the College of American Pathologists ... that meet stringent requirements around quality, accuracy and ... "Genos is committed to maintaining the highest ... to be receiving CAP accreditation," said Jill ...
(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
(Date:2/8/2017)... 7, 2017 Report Highlights ... The global synthetic-biology market reached ... by 2021, growing at a compound annual growth rate (CAGR) ... of the global markets for synthetic biology. - Analyses of ... and projections of compound annual growth rates (CAGRs) through 2021. ...
Breaking Biology News(10 mins):